Concourse Financial Group Securities, Inc. Immuno Gen, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 07, 2024
BUY
$12.46 - $29.95 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$14.09 - $19.87 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$14.09 - $19.87 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$3.75 - $20.05 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$3.67 - $4.92 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$4.55 - $6.31 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$4.48 - $6.47 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$3.15 - $5.76 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$4.26 - $7.48 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$4.75 - $7.5 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$5.02 - $6.59 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$5.79 - $8.6 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$6.5 - $10.53 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$3.7 - $7.66 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$3.45 - $4.89 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$3.32 - $5.34 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020
BUY
$2.12 - $6.8 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$2.25 - $5.8 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$2.22 - $3.39 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019
SELL
$1.8 - $3.3 $1,035 - $1,897
-575 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$3.94 - $9.7 $2,265 - $5,577
575 New
575 $2,000
Q3 2018

Nov 13, 2018
BUY
$8.6 - $11.26 $0 - $0
0 New
0 $0

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email